Body | Page 201 of 274 | SpiritIndia.com

Smoking :: Nabi biopharmaceuticals completes enrollment in nicvax phase iib ‘proof-of-concept’ clinical trial

Nabi Biopharmaceuticals (Nasdaq: NABI) today announced it has completed enrollment for its Phase IIB “proof-of-concept” study for NicVAX(R) (Nicotine Conjugate Vaccine), the company’s novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. Enrollment for the trial was completed three months earlier than anticipated, paving the way for the release of trial results early in the second quarter of 2007.

Obesity :: Manhattan pharmaceuticals – oral oleoyl-estrone clinical program to include morbidly obese

Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US Phase 2a clinical trial evaluating oral OE in morbidly obese male subjects will be initiated in October 2006. The morbidly obese population in the US is estimated to be 14 million people. OE is the Company’s orally administered product candidate in development for the treatment of obesity.

Health :: New research to cut animal testing, uk

Researchers at The University of Manchester have been awarded 130,000 pounds to develop new techniques to reduce the need for animals in drug testing. Current checks to establish whether a new drug is carcinogenic can be inconclusive and require further testing on live animals to establish whether they are harmful or not.

Hypertension :: High blood pressure in children linked with sleep breathing problems

Children with high blood pressure may be at risk for sleep breathing disorders, according to a small study reported at the American Heart Association’s 60th Annual Fall Conference of the Council for High Blood Pressure Research.

Breast Cancer :: Breast cancer risk dependent upon ethnic variations in hormone levels

Researchers have known that a woman’s natural hormone levels can affect her risk of developing breast cancer. A new study from the University of Southern California (USC) has found that the natural levels of estrogens in post-menopausal women varies by ethnicity and race, and may explain the differences in the groups’ breast cancer rates. The study appears in the October issue of Cancer Epidemiology, Biomarkers & Prevention.

Breast Cancer :: Regular exercise, keeping weight in check reduces breast-cancer risk in postmenopausal women

Postmenopausal women who want to significantly decrease their breast-cancer risk would be wise to exercise regularly and keep their weight within a normal range for their height, according to new findings from the Women’s Health Initiative to be published in the journal Obesity.

Breast Cancer :: Risk of anemia reduced by exercise in breast cancer patients

Women undergoing radiation treatment for breast cancer benefit from moderate intensity, regular aerobic activity, according to a new study. Published in the November 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study found that exercise improved the oxygen capacity of patients and maintained levels of red blood cells during radiation treatment. In contrast, women who did not exercise experienced significant declines in their oxygen capacity. This is the first study to investigate the effect of exercise during treatment.

Prostate Cancer :: Obesity independently impacts prostate cancer screening

When interpreting prostate cancer screening test results, physicians should consider the impact of a patient’s body mass index, regardless of race, according to a new study. Published in the November 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study found that obese African-American and Caucasian men had lower levels of prostate surface antigen (PSA) and free PSA (fPSA) than men with normal body mass index (BMI), suggesting that an obese man with a slightly elevated PSA may be at higher risk for prostate cancer than a man with normal BMI.

ADHD :: NRP104 (lisdexamfetamine dimesylate) for the treatment of adhd

Shire plc announced that its collaborative partner New River Pharmaceuticals Inc. (Nasdaq: NRPH) has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NRP104 (lisdexamfetamine dimesylate), for the treatment of pediatric Attention-Deficit/Hyperactivity Disorder (ADHD).

Nutrition :: Researchers look to solve mystery behind egcg and probiotics

When talking about nutrition, EGCG and probiotics are two words that we’ve been hearing a lot about these days. But most consumers don’t know what they are, where they are found and what they do. Some of that mystery was cleared up this week at the 47th Annual Symposia of the American College of Nutrition (ACN) where leading nutrition experts revealed new research about the health benefits of these two ingredients.